Proton pump inhibitors linked to fracture risk
Proton pump inhibitors (PPIs) are associated with a 29% increased risk of fracture, including a 31% increased risk of hip fracture and a 54% increased risk of vertebral fracture, according to a study published in the May/June 2011 issue of Annals of Family Medicine.
To investigate the association between the use of acid-suppressive drugs such as PPIs and histamine 2-receptor antagonists (H2RAs) and fracture risk, investigators searched MEDLINE (PubMed), EMBASE, and the Cochrane Library from beginning through December 2010, for case-control, nested case-control, and cohort studies.
The authors included 11 studies published between 1997 and 2011 in their meta-analysis: 5 case-control studies, 3 nested case-control studies, and 3 cohort studies. The authors found a moderate increase in the risk of fracture with PPI use compared with non-use; they found no association between the use of H2RAs and fracture. Long-term use of PPIs was associated with an increased risk of any fracture (adjusted OR=1.30; 95% CI, 1.15–1.48) and with hip fracture risk (adjusted OR=1.34; 95% CI, 1.09–1.66). Long-term H2RA use was not significantly associated with fracture risk. The results suggest that H2RAs and PPIs may have different effects on bone metabolism.
"Widespread use of PPIs with the potential risk of fracture is of great importance to public health. Clinicians should carefully consider their decision to prescribe PPIs for patients already having an elevated risk of fracture because of age or other factors,” the authors wrote. “It is not necessary to treat patients to the point of an achlorhydric state to resolve acid reflux symptoms, so we recommend that drug doses be chosen thoughtfully with consideration of what is necessary to achieve desired therapeutic goals.”
MORE ARTICLES IN THIS ISSUE
New competency reports for pharmacists and other healthcare professionals aim to set forth strategies that will help providers work together better.
U.S. pharmacies are ready and able to assist in the case of a national emergency, pharmacy officials recently told a Homeland Security subcommittee.
The National Community Pharmacists Association Conference taking place May 23 to May 25 in Washington, D.C., at the Hyatt Regency on Capitol Hill is focusing on how the expert medication counseling and new, nontraditional services provided by local pharmacists can help reduce costs and improve patient outcomes.
There is no safe therapeutic window of time for using NSAIDs in patients with prior myocardial infarction. Even short-term treatment with most NSAIDs appears associated with increased risk of death and recurrent MI, reported a study published in Circulation.
Allergic rhinitis patients are likely to have sleep disturbances and are not likely to be satisfied with the nasal sprays on the market, according to the new Nasal Allergy Survey Assessing Limitations 2010 study.